Health Innovation Fund

Obatala Sciences is a biotechnology company focused on developing an innovative in vitro humanized adipose tissue model system aimed at addressing the significant economic burden of obesity and diabetes. By treating body fat as a functional organ, the company seeks to enhance the understanding of its role in health and disease. Their three-dimensional screening tool simplifies tissue engineering, facilitating disease modeling, cell assays, cell identification, tissue analysis, and drug discovery. This model enables academic and pharmaceutical researchers to efficiently identify effective drug compounds, ultimately reducing the time, cost, and effort associated with testing potential treatments for obesity, diabetes, other metabolic diseases, and related cancers.

Prolira BV is a medical technology company based in Utrecht, the Netherlands, founded in 2015. It specializes in developing DeltaScan, an innovative EEG-based medical device designed for the early detection of delirium, a form of acute brain failure. The DeltaScan system comprises a single-use electrode patch known as the DeltaScan Patch and a hardware/software module called the DeltaScan Monitor, which analyzes brain activity to support clinical decision-making. Prolira is dedicated to enabling timely and effective treatment for acute encephalopathy and delirium, conditions that affect approximately 20 million patients annually in hospitals across the European Union and the United States. By providing the first EEG bedside device with a validated proprietary algorithm, Prolira aims to help clinicians optimize patient recovery, ultimately reducing long-term cognitive impairment and hospital costs.

FABPulous is a healthcare company based in the Netherlands, established in 2008 as a spin-off from Maastricht University. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created an innovative handheld disposable plasma separation device that enables the rapid preparation of plasma from a single drop of blood. This technology presents significant advantages for point-of-care and home testing compared to existing methods. The company's initial product focuses on a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which assists healthcare providers in the first-line diagnosis of acute myocardial infarction. By integrating their plasma preparation device with various in vitro diagnostic platforms, FABPulous aims to enhance the speed and accuracy of diagnostic testing.

Prolira BV is a medical technology company based in Utrecht, the Netherlands, founded in 2015. It specializes in developing DeltaScan, an innovative EEG-based medical device designed for the early detection of delirium, a form of acute brain failure. The DeltaScan system comprises a single-use electrode patch known as the DeltaScan Patch and a hardware/software module called the DeltaScan Monitor, which analyzes brain activity to support clinical decision-making. Prolira is dedicated to enabling timely and effective treatment for acute encephalopathy and delirium, conditions that affect approximately 20 million patients annually in hospitals across the European Union and the United States. By providing the first EEG bedside device with a validated proprietary algorithm, Prolira aims to help clinicians optimize patient recovery, ultimately reducing long-term cognitive impairment and hospital costs.

NightBalance B.V., established in 2009, is a medical technology company that develops innovative solutions to improve sleep quality. Originating from research at Delft University of Technology, the company specializes in creating a smart therapy device designed to treat positional obstructive sleep apnea. This medical device, the Sleep Position Trainer, measures a patient's sleep behavior and prevents apnea episodes, allowing users to achieve more comfortable and restful sleep.

FABPulous is a healthcare company based in the Netherlands, established in 2008 as a spin-off from Maastricht University. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created an innovative handheld disposable plasma separation device that enables the rapid preparation of plasma from a single drop of blood. This technology presents significant advantages for point-of-care and home testing compared to existing methods. The company's initial product focuses on a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which assists healthcare providers in the first-line diagnosis of acute myocardial infarction. By integrating their plasma preparation device with various in vitro diagnostic platforms, FABPulous aims to enhance the speed and accuracy of diagnostic testing.

DirectDerm is a medical consulting platform that connects patients and healthcare providers with board-certified dermatologists for immediate consultative services regarding skin-related medical issues. The platform enables the efficient transmission of patient history and images, facilitating rapid communication between patients or referring medical providers and dermatology specialists. By streamlining access to expert dermatological care, DirectDerm enhances the ability of medical providers to offer specialized treatment and skincare solutions for their patients' skin conditions.

FABPulous is a healthcare company based in the Netherlands, established in 2008 as a spin-off from Maastricht University. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created an innovative handheld disposable plasma separation device that enables the rapid preparation of plasma from a single drop of blood. This technology presents significant advantages for point-of-care and home testing compared to existing methods. The company's initial product focuses on a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which assists healthcare providers in the first-line diagnosis of acute myocardial infarction. By integrating their plasma preparation device with various in vitro diagnostic platforms, FABPulous aims to enhance the speed and accuracy of diagnostic testing.